| Name | Title | Contact Details |
|---|
AdPharma is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Provident Clinical Research and Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts. We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening. Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ever before, saving your team valuable time and resources.
Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.
Bioinformatics.org is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.